Why this biotech startup from Lund University is ready to go global
Gedea Biotech has developed a major new antibiotic-free treatment for vaginal infections and is about to take its product on the world stage. Discovered by a research team of three chemists and a gynecologist at Lund University, the treatment can be used for both bacterial and fungal infections.
“We are currently in the end phase of the clinical trials and are counting on launching an approved product during next year,” says Annette Säfholm, Gedea’s CEO.
According to Säfholm, Gedea’s product effectively treats vaginal infections caused by both bacteria and fungus and will be available without a prescription and sold over-the-counter (OTC), which is how most market competitors are sold. There are no current effective treatments on the market for both bacterial and fungal infections and very few OTC products that have shown to be very effective in treating those caused by bacteria. Additionally, consumers commonly mix up the two types of vaginal infections and often choose the wrong treatment.
“It feels incredibly exciting and motivating to be working with women’s health where we really need investments in new products, as well as working with alternatives to antibiotics,” says CEO Annette Säfholm.
Next stop: world-wide pharmaceutical sales
Säfholm explains that Gedea’s goal is to reach global distribution as quickly as possible, with Europe set as their first market for approval to be sold over the counter. More clinical trials are needed to be available in the United States, but Säfholm says the company’s next scheduled trials are specifically designed to meet the requirement for the U.S. market.
Gedea wants to find a global pharmaceutical company to handle the marketing and sales of their product. “Our intention is not to market and sell ourselves,” explains Säfholm. “We will be able to reach patients quicker than if you would try to build up sales channels on your own.”
“...Since the competition is extremely high, it is necessary to consult others for help.”
Initially backed by LU holding, the investment arm of Lund University’s innovation department that invests in startups based on research done at the university, Gedea Biotech has been approved for EU-funding, through the Horizon SME Instrument Phase 1, for the amount of €50 000.
Invest in Skåne helped Gedea in many different ways, and Säfholm says one of the organization’s instrumental support was in the assistance with their application for the Horizon SME Instrument Phase 1. The company had applied once before, but after Invest in Skåne’s individual consulting – they were approved.